Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

This study is testing whether giving targeted therapy (a drug called osimertinib or a similar EGFR inhibitor) after lung cancer surgery can be guided by a blood test that detects residual cancer DNA. Rather than giving all patients the same treatment, doctors would use this sensitive test to determine who still has cancer cells remaining after surgery and who actually needs additional treatment. **You may be eligible if:** - You are 18–79 years old - You have non-small cell lung cancer (NSCLC) with a specific EGFR gene mutation (exon 19 deletion, L858R, L861Q, or G719X) - Your lung cancer has been completely removed by surgery (stage IB–IIIB) - Your general health is good (ECOG score 0–1) - Your blood cell counts and organ function meet the required levels **You may NOT be eligible if:** - Your cancer has spread beyond what surgery can address - You have had prior EGFR-targeted drug treatment - You have serious liver, kidney, or heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.